Engineered immune cells take on Hard-to-Treat colon cancer
NCT ID NCT06675513
First seen May 12, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This early-phase study tests a new treatment called WD-01, which uses a patient's own immune cells modified to target a protein (GCC) found on colorectal cancer cells. The goal is to see if it is safe and can shrink tumors in people with metastatic colorectal cancer who have not responded to at least two prior treatments. Up to 30 participants will receive the therapy, and researchers will monitor side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Cancer Hospital
Hefei, Anhui, 710054, China
Conditions
Explore the condition pages connected to this study.